The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Green, a former pharmacist and pharma ad copywriter whose resume includes such agencies as Grey Healthcare and KPR (since ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

Bristol Myers Squibb Co. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a DNA-binding protein Ikaros (IKZF1 ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and ...